Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Understanding the world prescribers are living in allows for more meaningful customer interactions. MAP Training Programs build your knowledge on marketplace trends impacting providers and the pharmaceutical industry today.
Bring teams up-to-speed on the latest market access trends impacting their unique selling environment.
Subscribe to the Marketplace Blog to stay up-to-date on the latest trends impacting pharma
*required
Copay accumulator programs have only one purpose; increase profits for payers. Patients don’t gain an advantage, nor do manufacturers. On top of that, providers face the difficulty of helping patients manage a process they don’t understand. And somehow, the whole concept has gotten worse. Patient Assistance Programs offered by manufacturers are intended to relieve the patient’s financial burden when filling their prescription. From the patient perspective, this is great. This blog takes a closer look behind the curtains to reveal
The 340B Program remains controversial. Hospitals and other Covered Entities (providers qualified to buy drugs at 340B prices) that benefit from the program describe it as a lifeline that keeps them in business. Pharma sees 340B as a program that has grown well beyond its original purpose, and at their expense. This controversy has created fracture lines that run in many different directions. The fractures are being created by lawsuits, government regulations, federal law, and other factors. We’ll describe the
The Inflation Reduction Act (IRA) passed on August 16th, 2022 brings big changes for the pharmaceutical industry. On August 31st we had a live discussion on the law’s anticipated impact. Here is a summary of our discussion: Inflation Penalty The intent of the law is to impose penalties on manufacturers who raise drug prices faster than inflation. Penalties will begin very soon; however, recent Consumer Price Index (CPI) inflation rates allow increases of around 13.5% without any penalties assessed. Manufacturers
There are no upcoming events at this time
As the market access environment changes, relevant topics will be covered through new programs. Subscribe below to be the first to know about new MAP Program topics and added dates for existing Programs.
*required
